OakChart

Kamada Ltd

KMDAHealthcare·Drug Manufacturers - Specialty & Generic·Israel·Small·NASD·Nov 11 • 3:59 PM ET

8.13+0.03 (0.37%)
2026-11-12 02:35 CET
Market cap
467.32 USD m
Revenue, TTM
196.87 USD m
Net income, TTM
24.95 USD m
Free cash flow, TTM
36.36 USD m
EPS diluted, TTM
0.43
P/E
18.98
Compare

Price

KMDA against its 20, 50 and 200-day averages
2050200beatmiss
7.007.508.008.509.00233K467KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KMDAclose 8.1320-day 7.7050-day 8.06200-day 8.008.13

13.0% under the 52-week high of 9.35 on 25 Feb 2026. 52-week low 6.60 on 21 Nov 2025. Last 15 sessions, 20.4% high to low

Volume 0.87× normal · the line is the 50-bar volume average

Profile

KMDA
52-week range, 56% of the way up
6.599.35

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment refers to specialty plasma therapies and normal source plasma (NSP). The Distribution segment focuses on the commercialization of in-licensed third-party biopharmaceutical products. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Employees462
IPOMay 31, 2013
Beta0.92
ATR, 14d0.31
Rel volume0.87
Short float0.52%
Insider own45.13%
Inst own15.34%

Snapshot

6 groups

Valuation

Index-
Market Cap469.02M
Enterprise Value405.42M
Income24.95M
Sales196.87M
Book/sh4.65
Cash/sh1.31
Dividend Est.-
Dividend TTM0.42 (5.17%)
Dividend Ex-DateNov 19, 2026
Dividend Gr. 3/5Y- -
Payout-
Employees462
IPOMay 31, 2013

Ratios

P/E18.98
Forward P/E14.02
PEG0.65
P/S2.38
P/B1.75
P/C6.23
P/FCF12.90
EV/EBITDA8.84
EV/Sales2.06
Quick Ratio2.24
Current Ratio4.17
Debt/Eq0.04
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)0.43
EPS next Y0.58
EPS next Q0.11
EPS this Y33.01%
EPS next Y19.59%
EPS next 5Y21.66%
EPS past 3/5Y- -2.03%
Sales past 3/5Y11.74% 6.25%
EPS Y/Y TTM21.73%
Sales Y/Y TTM12.64%
EPS Q/Q50.87%
Sales Q/Q10.69%
EarningsNov 09 BMO
EPS/Sales Surpr.22.43% -0.90%

Ownership

Insider Own45.13%
Insider Trans-0.76%
Inst Own15.34%
Inst Trans-3.37%
ROA6.57%
ROE9.35%
ROIC8.98%
Gross Margin41.59%
Oper. Margin15.44%
Profit Margin12.67%
SMA205.56%
SMA500.88%
SMA2001.68%
Trades-

Technical

Shs Outstand57.69M
Shs Float31.65M
Short Float0.52%
Short Ratio1.20
Short Interest0.17M
52W High9.35 -13.05%
52W Low6.59 23.28%
Volatility3.98% 3.09%
ATR (14)0.31
RSI (14)56.25
Beta0.92
Rel Volume0.87
Avg Volume138.60K
Volume120,839

Performance

Perf Week9.57%
Perf Month5.72%
Perf Quarter11.98%
Perf Half Y3.44%
Perf YTD15.16%
Perf Year15.16%
Perf 3Y73.72%
Perf 5Y43.89%
Perf 10Y50.56%
Recom1.00
Target Price13.75
Prev Close8.10
Price8.13
Change %0.37%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Mar 21, 2025InitiatedTThe Benchmark CompanyBuy$15+84.5%
Jul 03, 2024InitiatedSStifelBuy$18+121.4%
Feb 02, 2018InitiatedCChardan Capital MarketsBuy$7-13.9%

Peers

Mkt cap
TickerCompanyMkt cap
ADMAAdma Biologics Inc2.93B
EBSEmergent Biosolutions Inc310.55M
GRFSGrifols SA ADR2.28B
TAKTakeda Pharmaceutical Co ADR66.58B
ETONEton Pharmaceuticals Inc1.97B
SIGASIGA Technologies Inc225.63M
BCRXBiocryst Pharmaceuticals Inc1.97B
ANIPANI Pharmaceuticals Inc1.63B
PLXProtalix BioTherapeutics Inc252.18M
MREOMereo Biopharma Group Plc ADR48.94M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Brenner YaelVP QualitySep 14 '26Option Exercise5.9326,964159,89712,766Sep 17 11:40 AM
Livneh NirVP, General CounselSep 14 '26Option Exercise5.3710,00053,70010,000Sep 17 11:37 AM
Tsur DavidDirectorSep 14 '26Sale8.1822,827186,725407,929Sep 17 11:33 AM
Tsur DavidDirectorSep 08 '26Sale8.26162,7601,344,398430,931Sep 11 11:29 AM
Tsur DavidDirectorSep 07 '26Sale8.2814,238117,891593,691Sep 11 11:29 AM
Tsur DavidDirectorSep 09 '26Sale8.261751,446430,756Sep 11 11:29 AM
Tsur DavidDirectorSep 02 '26Option Exercise6.7149,000328,690634,429Sep 08 07:00 AM
Brenner YaelVP QualitySep 02 '26Option Exercise5.943,03618,0349,302Sep 08 07:00 AM
Brenner YaelVP QualityAug 26 '26Option Exercise6.2530,000187,50016,266Aug 31 07:00 AM

Held by

AUM
TickerCompanyAUM
DISVDimensional International Small Cap Value ETFAUM: 5.11B
DFISDimensional International Small Cap ETFAUM: 5.82B
DFICDimensional International Core Equity 2 ETFAUM: 15.45B
AIMSAcuitas Small Cap Active ETFAUM: 82.88M
DFAXDimensional World ex U.S. Core Equity 2 ETFAUM: 12.02B
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200
  • Kamada Misses On Revenue But Raises Guidance As Margin Gains Carry The Quarter (Earnings Whispers) +6.64%
  • Kamada: Q3 Earnings Snapshot (Associated Press)
  • Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027 (GlobeNewswire)
  • Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year (GlobeNewswire)
  • Kamada's Record Second Quarter Faces A Durability Test As Unraised 2026 Guidance Looms (Earnings Whispers)
  • Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026 (GlobeNewswire)
  • Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026 (GlobeNewswire)
  • Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel (GlobeNewswire)
  • CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB Supply to Meet Increased Demand (GlobeNewswire) +5.86%
  • Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders (GlobeNewswire)
  • Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026 (GlobeNewswire)
  • Kamada Ltd (KMDA) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) +5.52%
  • Kamada: Q2 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-090.1560.1280.14052.0352.514
2026Q22026-08-120.1720.1130.16154.9250.844
2026Q12026-05-130.0840.1150.07245.2446.724
2025Q42026-03-110.0680.0780.05844.6845.424
2025Q32025-11-100.0920.0930.09247.0145.814
2025Q22025-08-130.1320.0900.12844.7544.664
2025Q12025-05-140.0730.0680.06944.0242.234
2024Q42025-03-050.0730.0530.06639.0139.453
2024Q32024-11-130.0740.0670.06741.7441.043
2024Q22024-08-140.0840.0570.07742.4739.713
2024Q12024-05-080.0440.0600.04137.7438.252
2023Q42024-03-060.0970.0500.08836.4337.702
2023Q32023-11-130.0660.0300.06037.9337.502
2023Q22023-08-160.0450.0200.04037.4434.202
2023Q12023-05-240.0000.025-0.04030.7134.302
2022Q42023-03-150.0750.0650.06645.4444.642

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.5790.5490.548127.2128.15
2020FY0.4010.4190.384133.25134.75
2021FY-0.0380.040-0.050103.6494.41
2022FY-0.025-0.050-0.052129.34128.54
2023FY0.2140.1250.154142.52143.8
2024FY0.2650.2430.250160.95161.2
2025FY0.3650.3680.350180.46181.2
2026FY-0.485--205.25
2027FY-0.580--229.99
2028FY-0.657--251.39
2029FY-0.785--271.7
2030FY-0.970--288.8

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0943052.0046.1554.37
2026Q4S2026-10-2740150.2846.1552.74
2026Q4S2026-10-2640250.2846.1552.74
2026Q4S2026-09-2440450.2846.1552.74
2026Q4S2026-08-1340350.6046.1552.74
2026Q4S2026-08-1240251.2748.8652.74
2026Q4S2026-07-2940052.0548.8654.50
2026Q4S2026-07-2741052.0548.8654.50
2026Q4S2026-05-1542152.0548.8654.50
2026Q4S2026-05-1341151.8048.8653.50
2026Q4S2026-03-1141052.2151.4553.50
2026Q4S2026-01-0730051.5851.5051.66
2026Q4S2026-01-0620051.5851.5051.66
2026Q4S2025-12-1820051.3351.0051.66

Estimate history

EPS, annual0.180.5510.5480.384-0.05-0.0520.1540.250.3460.4284
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0670.0660.0690.1280.0920.0580.0720.1610.139
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual102.825114.469127.187133.246103.642129.339142.519160.953180.46196.87
Period201720182019202020212022202320242025TTM
Sales, quarterly41.7439.00544.01844.75447.0144.67845.2454.92152.034
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual40.26340.29540.35344.74344.844.83357.4857.50557.68657.694
Period201720182019202020212022202320242025MRQ
Shares, quarterly57.48657.50557.50557.50557.68157.68657.68657.69457.694
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue196.87180.46160.95142.52129.34103.64133.25127.19114.47
Cost of Goods Sold Incl. D&A114.99108.1494.9390.7486.2475.3087.3478.9873.84
Gross Profit81.8972.3266.0251.7843.1028.3545.9048.2140.63
Selling, General and Administrative Excl. Other51.4846.0945.3740.8037.6628.2926.6225.2421.06
Research and Development9.5912.2514.5413.3512.6010.7412.8812.409.75
Other Operating Expense-0.000.00--0.00-0.00-
Operating Income30.4026.2320.6510.985.440.0619.2922.9719.57
Interest Expense1.060.860.661.300.911.280.270.290.34
Unusual Expense-0.042.798.220.835.720.571.000.37-
Net Income Before Taxes30.0223.4713.338.43-2.26-1.8918.5722.9820.34
Income Taxes5.083.27-1.130.150.060.351.430.73-1.96
Consolidated Net Income24.9520.2014.468.28-2.32-2.2317.1422.2522.30
Net Income From Continuing Operations24.9520.2014.468.28-2.32-2.2317.1422.2522.30
Net Income24.9520.2014.468.28-2.32-2.2317.1422.2522.30
EPS (Recurring)0.430.380.350.170.04-0.040.400.550.55
EPS (Basic, Before Extraordinaries)0.430.350.250.17-0.05-0.050.390.550.55
EPS (Diluted)0.430.350.250.15-0.05-0.050.380.550.55
EBITDA45.8741.1533.8723.6917.605.6724.1827.4823.27
Non-Operating Income (Expense)0.640.891.56-0.42-1.07-0.100.540.681.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.600.650.671.010.880.410.750.900.72
Price To Earnings Ratio18.7318.7321.6543.84--16.2510.308.78
Price To Sales Ratio2.532.292.182.311.352.852.152.191.77
Gross Margin41.5940.0841.0236.3333.3227.3534.4537.9035.49
Operating Margin15.4414.5412.837.714.210.0514.4718.0617.10
Net Margin12.6711.198.995.81-1.79-2.1512.8617.4919.48
Shares Outstanding57.6957.6957.5157.4844.8344.8044.7440.3540.30
Market Capitalization467.32467.32340.34341.95174.64286.49281.78268.99195.73

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue52.0354.9245.2444.6847.0144.7544.0239.01
Cost of Goods Sold Incl. D&A28.7032.4526.1227.7127.2525.8323.2721.97
Gross Profit23.3422.4719.1216.9719.7618.9320.7517.03
Selling, General and Administrative Excl. Other12.9512.9612.1613.4211.9611.8412.9511.36
Research and Development2.322.202.182.892.643.224.252.67
Other Operating Expense-0.000.000.00--0.000.00
Operating Income10.399.516.953.557.807.087.795.67
Interest Expense0.240.370.190.260.220.190.190.19
Unusual Expense0.88-1.051.54-1.411.680.611.782.77
Net Income Before Taxes9.7110.195.394.736.375.756.612.46
Income Taxes1.720.931.261.171.07-1.622.65-1.35
Consolidated Net Income7.999.264.133.565.307.383.963.81
Net Income From Continuing Operations7.999.264.133.565.307.383.963.81
Net Income7.999.264.133.565.307.383.963.81
EPS (Recurring)0.150.150.090.040.110.140.090.10
EPS (Basic, Before Extraordinaries)0.140.160.070.060.090.130.070.07
EPS (Diluted)0.140.160.070.060.090.130.070.07
EBITDA14.3113.4010.807.3511.5610.8311.419.77
Non-Operating Income (Expense)0.430.000.160.040.46-0.530.79-0.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.550.700.350.090.070.140.13
Price To Earnings Ratio18.7320.7623.7719.8820.9927.7426.2721.65
Price To Sales Ratio2.532.212.622.422.302.642.272.17
Gross Margin44.8540.9142.2537.9842.0442.3047.1443.66
Operating Margin19.9717.3215.377.9516.6015.8317.7114.53
Net Margin15.3616.869.137.9711.2716.489.019.76
Shares Outstanding57.6957.6957.6957.6957.6857.5157.5157.51
Market Capitalization467.32423.48481.06407.23399.08445.66380.11340.34

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments75.4778.4455.6434.2618.59109.2773.9150.5943.02
Short Term Receivables29.0423.2521.4428.3635.6323.5025.2329.9031.97
Inventories84.9478.8288.4872.5271.8343.0443.1729.3221.07
Other Current Assets3.623.854.413.883.992.101.251.090.82
Total Current Assets193.07184.35169.96139.00130.04177.91143.56110.8996.88
Net Property, Plant & Equipment50.2745.8635.9828.7329.4029.1228.5725.0025.18
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable7.548.028.497.585.562.06---
Intangible Assets126.41132.17139.96147.01153.591.490.300.12-
Deferred Tax Assets0.000.49---0.001.312.05-
Other Assets1.421.370.510.060.070.080.050.050.05
Total Assets378.71372.25354.91322.38318.67210.66173.80138.12122.11
Short Term Debt Incl. Current Port. of LT Debt2.121.631.385.463.791.311.510.560.61
Accounts Payable23.2427.7324.8032.9225.1016.1124.8317.2818.04
Other Current Liabilities22.0320.0223.4137.3325.177.556.405.7210.75
Total Current Liabilities47.3949.3949.5975.7054.0624.9732.7423.5729.40
Long Term Debt9.449.437.4415.1420.573.634.240.721.37
Provision for Risks Charges0.670.510.620.671.281.411.270.791.14
Deferred Tax Liabilities1.65--------
Other Liabilities50.4853.4653.2354.8465.942.020.230.670.71
Total Liabilities109.64112.79110.89146.36141.8432.0338.4825.7432.62
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity269.07259.46244.02176.02176.82178.64135.32112.3889.49
Total Shareholders Equity269.07259.46244.02176.02176.82178.64135.32112.3889.49
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity269.07259.46244.02176.02176.82178.64135.32112.3889.49
Total Liabilities & Stockholders Equity378.71372.25354.91322.38318.67210.66173.80138.12122.11
Book Value Per Share4.664.514.253.933.953.993.352.792.22
Tangible Book Value Per Share2.472.211.810.650.523.963.352.792.22
Full-Time Employees462420378380355408429408413
Price to Book Ratio1.741.331.431.011.621.582.381.742.01
Return on Assets5.383.982.45-0.72-0.848.9214.2717.146.22
Return on Equity7.645.743.94-1.32-1.2510.9217.9722.098.83
Return on Invested Capital7.255.383.29-1.21-1.139.4015.9419.717.60
Quick Ratio2.282.141.640.881.085.403.073.462.58
Current Ratio4.073.733.431.842.417.134.394.703.30

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income25.4920.2014.468.28-2.32-2.2317.1422.2522.30
Depreciation15.9114.9213.8112.7112.165.614.904.523.70
Other Funds (Non Cash)9.158.067.911.527.102.212.841.790.56
Funds from Operations50.5543.1736.1822.5216.945.5926.2129.2924.61
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.48-17.6811.41-18.2011.65-14.41-7.10-1.72-14.07
Cash from Operating Activities46.0725.4947.594.3228.59-8.8219.1127.5710.55
Capital Expenditures-9.71-9.85-10.74-5.85-3.78-3.73-5.49-2.30-2.88
Net Assets From Acquisitions0.000.000.000.000.00-96.400.000.00-
Sale of Fixed Assets and Businesses0.010.010.000.010.000.000.010.010.03
Purchase or Sale of Investments0.000.000.000.000.0039.08-7.651.73-2.32
Purchase of Investments0.000.000.000.000.00--7.65--2.32
Sale Or Maturity of Investments0.000.000.000.000.0039.08-1.73-
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-9.70-9.84-10.74-5.84-3.78-61.05-13.13-0.56-5.18
Cash Dividends Paid-24.49-11.530.000.000.000.000.000.000.00
Change in Capital Stock0.010.050.0158.240.010.0224.960.020.01
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.010.050.0158.240.010.0224.960.020.01
Proceedsfrom Stock Options0.000.000.0058.230.000.0024.900.000.00
Issuance or Reduction of Debt, Net0.000.000.00-17.41-2.6319.80-0.49-0.48-0.60
Change in Long Term Debt0.000.000.00-17.41-2.6319.80-0.49-0.48-0.60
Issuance of Long Term Debt0.000.000.000.000.0020.000.000.000.00
Reduction of Long Term Debt-0.000.00-17.41-2.63-0.21-0.49-0.48-0.60
Net Financing Active Other Cash Flow-6.60-5.89-12.67-17.30-5.630.000.000.000.00
Other Financing Activities Uses-6.60-5.89-12.67-17.30-5.630.000.000.000.00
Cash from Financing Activities-32.58-18.35-13.9122.68-9.3418.5923.36-1.53-0.59
Exchange Rate Effect-0.36-0.27-0.150.230.21-0.33-1.81-0.910.63
Net Change in Cash3.43-2.9722.7921.3815.67-51.6127.5424.575.41
Free Cash Flow36.3615.6436.85-1.5324.80-12.5513.6225.277.66
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow41.91100.679.52-7.03-21.0811.0226.40
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.001.330.73-1.94

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments75.3270.1373.1575.4772.0065.98
Short Term Receivables32.2242.5740.6529.0435.3235.20
Inventories92.7086.8885.4484.9485.4182.08
Other Current Assets---3.62--
Total Current Assets200.25199.57199.24193.07192.73183.27
Net Property, Plant & Equipment52.6952.0050.3750.2747.2947.14
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets30.3130.3130.31126.4130.3130.31
Deferred Tax Assets---0.000.000.00
Other Assets92.2893.9795.681.4299.1999.64
Total Assets382.72383.16383.02378.71377.21368.17
Short Term Debt Incl. Current Port. of LT Debt2.332.292.202.121.911.87
Accounts Payable26.4828.3521.9423.2424.8825.08
Other Current Liabilities19.2518.5235.6422.0321.0518.83
Total Current Liabilities48.0649.1659.7847.3947.8445.77
Long Term Debt9.399.529.449.449.569.55
Provision for Risks Charges0.810.820.710.670.590.57
Deferred Tax Liabilities5.463.822.871.651.720.66
Other Liabilities50.6250.2950.8450.4852.2751.67
Total Liabilities114.35113.60123.63109.64111.98108.22
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity268.37269.56259.39269.07265.23259.95
Total Shareholders Equity268.37269.56259.39269.07265.23259.95
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity268.37269.56259.39269.07265.23259.95
Total Liabilities & Stockholders Equity382.72383.16383.02378.71377.21368.17
Book Value Per Share4.654.674.504.664.604.52
Tangible Book Value Per Share4.134.153.972.474.073.99
Full-Time Employees---462--
Price to Book Ratio1.741.631.791.541.541.77
Return on Assets6.575.925.375.385.615.29
Return on Equity9.358.407.977.647.867.44
Return on Invested Capital2.883.321.541.281.932.74
Quick Ratio2.242.291.902.282.242.21
Current Ratio4.174.063.334.074.034.00

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income7.729.614.134.036.017.42
Depreciation3.774.093.854.204.243.78
Other Funds (Non Cash)3.191.283.850.843.230.13
Funds from Operations14.6914.9711.839.0613.4711.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.863.55-12.12-0.77-2.27-3.28
Cash from Operating Activities19.5418.52-0.298.2911.208.05
Capital Expenditures-3.50-2.19-0.97-3.05-3.90-2.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.000.000.000.000.00
Purchase or Sale of Investments41.70-1.48-40.230.000.000.00
Purchase of Investments41.70-1.48-40.230.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities38.21-3.66-41.20-3.05-3.90-2.03
Cash Dividends Paid-9.53-14.790.00-0.17-0.48-11.58
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt--0.000.00--
Net Financing Active Other Cash Flow-0.73-4.23-0.47-1.18-0.54-4.20
Other Financing Activities Uses-0.73-4.23-0.47-1.18-0.54-4.20
Cash from Financing Activities-10.71-19.51-0.86-1.51-1.47-16.19
Exchange Rate Effect-0.020.02-0.20-0.15-0.07-0.15
Net Change in Cash47.02-4.63-42.553.595.77-10.32
Free Cash Flow16.0416.34-1.265.247.316.02
Price to Free Cash Flow41.9134.8793.61100.3158.7022.30

Revenue breakdown

Distribution2024: 19.51M 2025: 24.25M
Proprietary Products2024: 141.45M 2025: 156.21M
Asia2024: 2.38M 2025: 6.72M
Canada2024: 9.46M 2025: 10.81M
Europe2024: 4.94M 2025: 9.45M
Foreign countries2024: 100.50M 2025: 99.64M
Israel2024: 25.01M 2025: 29.56M
Latin America2024: 18.61M 2025: 24.22M
Other countries2024: 62.00K 2025: 56.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.52%0.2M31.7M124.85K
2026-10-150.62%0.2M31.7M120.00K
2026-09-300.66%0.2M31.7M112.31K
2026-09-150.51%0.2M31.7M100.47K
2026-08-310.50%0.2M31.5M78.42K
2026-08-140.48%0.1M31.5M55.00K
2026-07-310.42%0.1M31.5M44.74K
2026-07-150.42%0.1M31.5M45.06K
2026-06-300.49%0.2M31.5M45.97K
2026-06-150.36%0.1M31.3M54.17K
2026-05-290.43%0.1M31.3M60.00K
2026-05-150.46%0.1M31.3M62.54K
2026-04-300.33%0.1M31.3M64.53K
2026-04-150.35%0.1M31.3M71.47K
2026-03-310.52%0.2M31.3M80.75K
2026-03-130.45%0.1M31.3M74.36K
2026-02-270.44%0.1M31.3M84.21K
2026-02-130.53%0.2M31.3M83.08K
2026-01-300.25%0.1M31.3M82.60K
2026-01-150.27%0.1M31.3M81.18K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.503.007.306.0016.7021.000.000.938-0.0730.002
call5.000.655.503.7010.36626.000.000.856-0.0680.003
call7.500.001.451.002.30017.000.000.656-0.0620.005
call10.000.000.200.101.32936.000.000.180-0.0250.003
call12.500.001.002.092.3031.000.000.153-0.0390.003
call15.000.001.200.002.9130.000.000.130-0.0440.003
call17.500.001.450.003.3920.000.000.117-0.0480.002
put2.500.001.000.008.6150.000.00-0.061-0.0740.002
put5.000.000.550.351.8881.000.00-0.043-0.0120.001
put7.500.000.850.702.35911.000.00-0.343-0.0620.005
put10.000.204.903.107.3316.000.00-0.787-0.0300.004
put12.502.457.000.007.5210.000.00-0.845-0.0390.003
put15.005.209.500.008.2810.000.00-0.869-0.0440.003
put17.507.1012.000.008.8780.000.00-0.882-0.0470.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-06SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-09-15EFFECTEffectiveness filing by commission orderSEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-07SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.65M4
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Phoenix Financial Ltd.2.86%
RENAISSANCE TECHNOLOGIES LLC1.29%
WELLS FARGO & COMPANY/MN1.03%
ACADIAN ASSET MANAGEMENT LLC0.78%
DIMENSIONAL FUND ADVISORS LP0.57%
ARK Investment Management LLC0.46%
Huntleigh Advisors, Inc.0.29%
TWO SIGMA INVESTMENTS, LP0.26%
RENAISSANCE GROUP LLC0.22%
MARSHALL WACE, LLP0.13%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND7.80%
Fidelity Low-Priced Stock Fund7.19%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND6.15%
Invesco International Corporate Bond ETF2.17%
Artisan Global Equity Fund1.80%
Fidelity Low-Priced Stock K6 Fund1.43%
PACE Alternative Strategies Investments1.19%
DFA INTERNATIONAL SMALL CAP VALUE PORTFOLIO0.81%
iShares Core International Aggregate Bond ETF0.78%
THE CONTINENTAL SMALL COMPANY SERIES0.74%

OakChart. KMDA. Cached 15 minutes.